Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 30, 2023

BUY
$9.3 - $16.6 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023

BUY
$9.3 - $16.6 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023

BUY
$7.66 - $16.46 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023

BUY
$1.46 - $12.54 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023

BUY
$0.41 - $4.54 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022

BUY
$1.06 - $2.96 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022

BUY
$2.53 - $4.35 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022

BUY
$4.07 - $9.0 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022

BUY
$8.11 - $13.91 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021

BUY
$13.31 - $22.53 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021

BUY
$15.95 - $19.6 $0 - $0
0 New
0 $0

Others Institutions Holding AMAM

About Ambrx Biopharma Inc.


  • Ticker AMAM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,618,400
  • Market Cap $1.08B
  • Description
  • Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...
More about AMAM
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.